Keytruda

This page shows the latest Keytruda news and features for those working in and with pharma, biotech and healthcare.

Keytruda begins pursuit of rivals in small cell lung cancer

Keytruda begins pursuit of rivals in small cell lung cancer

Set for competition with Opdivo. Merck &Co. has gained approval for Keytruda for use in third line treatment of small cell lung cancer (SCLC). ... Merck is already exploring Keytruda’s use in combination with chemotherapy in a phase 3 KEYNOTE-604 study.

Latest news

More from news
Approximately 122 fully matching, plus 193 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast. ... On 28 December, Keytruda gained FDA clearance for use in Merkel cell carcinoma.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1 inhibitor Keytruda (pembrolizumab) was backed for cancers harbouring a biomarker known as microsatellite instability-high (MSI-H). ... Merck/MSD looks to have gained a dominant position in checkpoint inhibitor immuno-oncology (IO) with Keytruda – but

  • The UK’s new five-year pricing agreement The UK’s new five-year pricing agreement

    of this include recent deals on CAR-T therapies, plus a new expansion in the use of Keytruda in lung cancer, announced late last year.

  • Is China ready for a pharmaceutical gold rush?

    Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels. ... In light of recent clinical data, Keytruda is widely regarded as the better of the two checkpoint inhibitors in lung cancer.

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.